Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan-Mar;6(1):26-30.
doi: 10.4103/0976-7800.153615.

Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding

Pallavi C Dhamangaonkar  1 , K Anuradha  1 , Archana Saxena  1
Affiliations

Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding

Pallavi C Dhamangaonkar et al. J Midlife Health. 2015 Jan-Mar.

Abstract

Introduction: To study the efficacy of levonorgestrel intrauterine system (LNG-IUS; Mirena) in conservative management of abnormal uterine bleeding (AUB).

Materials and methods: Seventy women between 30 and 55 years with AUB were included in a study conducted over a period of 3 years. Response was assessed monthly for first 4 months and then yearly for maximum 2 years.

Results: Mirena caused a 80% decrease in median menstrual blood loss (MBL) at 4 months, 95% decrease in MBL by 1 year, and 100% decrease (amenorrhea) by 2 years. Mean hemoglobin (Hb) % showed a significant rise of 7.8% from baseline 4 months post Mirena insertion. Mirena acted as an effective contraceptive in women not using any other form of contraception. Hysterectomy could be avoided in most of the women.

Conclusion: Mirena provides an incredible nonsurgical alternative in treatment of menorrhagia. Its effects are reversible and it is an excellent fertility-sparing device. It is also an effective contraceptive.

Keywords: Abnormal uterine bleeding; contraceptive; mirena.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Wright RC. Hysterectomy: Past, present, and future. Obstet Gynecol. 1969;33:560–3. - PubMed
    1. Hidalgo MM, Hidalgo-Regina C, Bahamondes MV, Monteiro I, Petta CA, Bahamondes L. Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception. 2009;80:84–9. - PubMed
    1. Seeber B, Ziehr SC, Gschliesser A, Moser C, Mattle V, Seger C, et al. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception. 2012;86:345–9. - PubMed
    1. Lumsden M, Stanton SL, editors. Gynaecology. 2nd ed. London: Churchill Livingstone; 1997. pp. 421–39.
    1. Dean G, Schwarz EB. Intrauterine contraceptives (IUCs) In: Hatcher RA, Trussell J, Nelson AL, Gates W Jr, Polkar MS, Kowal D, editors. Contraceptive technology. 20th revised ed. New York: Ardent Media; 2011. pp. 147–91.